{"id":"NCT03961009","sponsor":"Kedrion S.p.A.","briefTitle":"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients","officialTitle":"A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-30","primaryCompletion":"2020-12-21","completion":"2020-12-21","firstPosted":"2019-05-23","resultsPosted":"2022-01-27","lastUpdate":"2025-04-13"},"enrollment":47,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Kedrion IVIG 10%","otherNames":[]}],"arms":[{"label":"Kedrion IVIG 10%","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).","primaryOutcome":{"measure":"Incidence Rate of Acute Serious Bacterial Infections (ABSIs)","timeFrame":"Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)","effectByArm":[{"arm":"Kedrion IVIG 10%","deltaMin":0,"sd":0}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":22},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":47},"commonTop":["Headache","Fatigue","Nausea","Sinusitis","upper respiratory tract infection"]}}